Phillygenin Attenuated Colon Inflammation and Improved Intestinal Mucosal Barrier in DSS-induced Colitis Mice via TLR4/Src Mediated MAPK and NF-κB Signaling Pathways.

Ulcerative colitis (UC) is a chronic, relapsing, and nonspecific inflammatory bowel disease (IBD). Phillygenin (PHI), a natural bioactive ingredient, isolated from Forsythiae Fructus, exhibits anti-inflammatory, anti-oxidative, and hepatoprotective activities. However, few reports provide direct evidence on the efficacy of PHI in improving colitis mice. The present study elucidated that the symptoms of DSS-induced colitis mice were alleviated after PHI administration, including body weight loss, the disease activity index, colon length shortening, colonic pathological damage, splenomegaly, and hepatomegaly. PHI treatment improved the intestinal mucosal barrier by protecting goblet cells, promoting gene expressions of Clca1, Slc26a3, and Aqp8, increasing tight junction proteins (TJs), and reducing epithelial cell apoptosis. In addition, the levels of oxidative stress (MPO, SOD, and MDA) and inflammatory cytokines (TNF-α, IL-1ß, IL-6, and IL-10) were reversed by PHI in colitis mice. According to transcriptome and network pharmacology analysis, inflammatory pathway might be an important mechanism for PHI to improve colitis. Western blotting displayed that the PHI inhibited the activation of tyrosine kinase Src mediated by TLR4, and then reduced the phosphorylation of downstream proteins p38, JNK, and NF-κB in colitis mice. In summary, our results suggested that PHI might be an appropriate and effective drug candidate to protect colitis.

MRI Radiomics Signature of Pediatric Medulloblastoma Improves Risk Stratification Beyond Clinical and Conventional MR Imaging Features.

BACKGROUND: Prognostic evaluation is important for personalized treatment in children with medulloblastoma (MB). Limited data are available for risk stratification using a radiomics-based model. PURPOSE: To evaluate the incremental value of an MRI radiomics signature in stratifying the risk of pediatric MB in terms of overall survival (OS). STUDY TYPE: Retrospective. SUBJECTS: A total of 111 children (mean age 5.82 years) with pathologically confirmed MB divided into training and validation cohorts (77 and 34 children, respectively). FIELD STRENGTH/SEQUENCE: A 3 T, contrast-enhanced T1-weighted imaging with inversion recovery. ASSESSMENT: The study endpoint was OS defined as the time between the preoperative MRI study and death or last follow-up. The radiomics signature model and a clinical-MRI model were developed for personalized OS prediction. An integrative model, which combined the radiomics signature and clinical-MRI features, was also built using multivariable Cox regression model. The performance of the three models was evaluated with the C-index. The performance of integrative model was assessed by calibration curve and decision curve analysis (DCA). STATISTICAL TESTS: Independent T-test, Mann-Whitney U test, Fisher's exact tests or chi-square test, logistic regression analysis, Kaplan-Meier survival analysis, C-index, intraclass correlation coefficients (ICC). P < 0.05 was considered statistically significant. RESULTS: The media OS was 2.83 years (3.87 ± 1.85 years). Two clinical and one conventional MR imaging features (remnant, adjuvant treatment, and peritumoral edema) were selected for clinical-MRI model building. The integrative model evaluated OS (C-index 0.823) better than either the radiomics signature (C-index 0.702) or the clinical-MRI model (C-index 0.771). And it also showed good performance in the validation cohort (C-indices: 0.786, 0.756, 0.721), which was validated by the good calibration (P > 0.05) and more benefit. DATA CONCLUSIONS: This study demonstrated that the integrative model, which combined radiomics signature, clinical, and conventional MRI features, showed best performance in OS evaluation for children with MB. The radiomics signature may confer incremental value over clinical-MRI features. EVIDENCE LEVEL: 3. TECHNICAL EFFICACY: Stage 2.

Naphthol-based fluorescent sensors for aluminium ion and application to bioimaging.

Three naphthol Schiff base-type fluorescent sensors, 1,3-Bis(2-hydroxy-1-naphthylideneamino)propane (L1), 1,3-Bis(1-naphthylideneamino)-2-hydroxypropane (L2) and 1,3-Bis(2-hydroxy-1-naphthylideneamino)-2-hydroxypropane (L3), have been synthesized. Their recognition abilities for Al(3+) are studied by fluorescence spectra. Coordination with Al(3+) inhibited the CN isomerization of Schiff base which intensely increase the fluorescence of L1-L3. Possessing a suitable space coordination structure, L3 is a best selective probe for Al(3+) over other metal ions in MeOH-HEPES buffer (3/7, V/V, pH=6.6, 25°C, λem=435nm). A turn-on ratio over 140-fold is triggered with the addition of 1.0 equiv. Al(3+) to L3. The binding constant Ka of L3-Al(3+) is found to be 1.01×10(6.5)M(-1) in a 1:1 complex mode. The detection limit for Al(3+) is 0.05µM. Theoretical calculations have also been included in support of the configuration of the L3-Al(3+) complex. Importantly, the probe L3 has been successfully used for fluorescence imaging in colon cancer SW480 cells.